Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Sends Amgen/UCB Evenity Back With BRIDGE Request

Executive Summary

The US FDA has surprised no-one with a Complete Response Letter for Amgen and UCB's novel osteoporosis treatment Evenity but, with luck, analysts say the product might still reach the market in 2018-19 and garner sales over £500m.


Related Content

Keeping Track: Tpoxx Wins Green Light For Smallpox, Submissions Galore, And A Broader Approval For Xtandi
Amgen Puts Evenity Filing Back On Track With TIMI Cardiovascular Risk Review
EU Filings For Amgen/UCB’s Evenity, iv Relenza From GSK, And A New PRIME Product
Amgen Focuses On Pipeline As Mature Products Face Declining Demand
Amgen Beats Consensus, Raises Earnings Guidance, But Is It Sustainable?
Keeping Track Of Novel Agents: US FDA Approves Nerlynx And Vosevi, Turns Down Evenity; Macrilen Returns
Radius's Tymlos Dawdles At CHMP, No EU Opinion Yet
Radius Prices Osteoporosis 'Blockbuster' Tymlos To Compete, Grow Market
Amgen/UCB Poised For Osteoporosis Drug Filing On Back Of Mixed PhIII


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts